Results 281 to 290 of about 1,262,069 (384)

Coronary spasm, coronary thrombosis and myocardial infarction.

, 1982
James E. Dalen, Ira S. Ockene, Joseph S. Alpert   +2 more
openalex   +1 more source

Anticoagulants in Coronary Thrombosis

, 1949
Lewis, J. A.
openalex   +1 more source

Experimental Myocardial Infarction: Induction of Coronary Thrombosis in the Intact Closed‐Chest Dog

Circulation Research, 1961
Andres E. Salazah
semanticscholar   +1 more source

The Space Within: How Architected Voids Promote Tissue Formation

Advanced Materials, Volume 38, Issue 7, 2 February 2026.
This review explores the role of void spaces in tissue engineering scaffolds and examines four key methods for introducing porosity into hydrogels at different scales. It discusses sacrificial templating, microgels, phase separation, and 3D printing, highlighting principles, advantages, and limitations. It also addresses emerging strategies integrating
Anna Puiggalí‐Jou, Isabel B. Hui, Carla Fernandez‐Rico, Marcy Zenobi‐Wong   +3 more
wiley   +1 more source

Comprehending the Membrane Properties for Emulation in Organs‐on‐a‐Chip

Advanced NanoBiomed Research, Volume 6, Issue 2, February 2026.
The advent of organ‐on‐chip models allows closer emulation of in vivo conditions, leading to effective, less costly, and specific drugs. Although a number of membrane‐based on‐chip models exist, better emulating functional models need to be devised for organ simulations.
Tanmayee Makarand Sathe, Dhananjay Shrikrishna Bodas   +1 more
wiley   +1 more source

Optimal antiplatelet therapy in patients with acute coronary syndrome and chronic kidney disease: for the Jerusalem platelets thrombosis and intervention in cardiology (JUPITER-11) study group [PDF]

Perel Nimrod, M David, Taha Louay, Meir Tabi, Itshak Amsalem, Rafi Hitter, Tomer Maller, Nir Levy, Lior Lupu, Hezzy Shmueli, Sharon Bruoha, Tal Cohen, Michael Glikson, Elad Asher   +13 more
openalex   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 329-347, February 2026.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source